Understanding and predicting colitis in cancer patients treated with immunotherapy
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients
This study is looking at how often patients with melanoma experience a serious gut issue when treated with two immunotherapy drugs, and it aims to find out what might increase the risk of this side effect, so we can better understand and help those affected.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10887508 on NIH RePORTER |
What this research studies
This research investigates the occurrence of immune-related colitis in patients receiving a combination of two immunotherapy drugs for melanoma. By analyzing patient samples and data, the team aims to identify risk factors that contribute to this serious side effect, which can lead to life-threatening complications. The study involves collaboration among experts in inflammatory bowel disease, tumor immunology, and microbiome research to ensure a comprehensive approach. Patients may undergo assessments that include blood tests and biopsies to better understand their individual responses to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients undergoing treatment with ipilimumab and nivolumab who may be at risk for developing immune-related colitis.
Not a fit: Patients who are not receiving immunotherapy or those with conditions unrelated to melanoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer immunotherapy treatments for cancer patients, reducing the risk of severe side effects.
How similar studies have performed: Previous research has shown that understanding immune-related adverse events can improve treatment safety, indicating potential for success in this area.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Gnjatic, Sacha — Icahn School of Medicine at Mount Sinai
- Study coordinator: Gnjatic, Sacha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.